Veru, Inc. CEO Mitch Steiner Discusses Recent Enobosarm Data and Preserving Muscle While on GLP-1 Obesity Drugs Artwork

WTR Biotech Spotlight

WTR Biotech Spotlight is a biweekly conversation with biotech executives, medical experts, and investors on recent clinical data or industry-driving events in biotech.

All Episodes

WTR Biotech Spotlight

Veru, Inc. CEO Mitch Steiner Discusses Recent Enobosarm Data and Preserving Muscle While on GLP-1 Obesity Drugs

February 26, 2025 • Season 1 • Episode 3

CEO Mitch Steiner joins us on this week’s WTR Biotech Spotlight to talk about the next generation of drugs focusing on lean mass (muscle) preservation for obesity patients on the popular GLP-1 therapies. He reviews the recent enobosarm Phase 2b data and highlights the importance of functional clinical benefit in addition to maintaining lean mass. Listen to learn more about Veru and its obesity drug enobosarm